3 Reasons AbbVie Is a Better Bargain Than You Might Think

At first glance, the picture for AbbVie (NYSE: ABBV) looks bad. The company's top-selling drug that generated over half of the company's total revenue in the past has lost patent exclusivity in Europe and will do so in the U.S. within the next three years. Last year, while the overall market skyrocketed AbbVie's shares fell 4%.

But I think that AbbVie is a much better bargain right now than you might think. Here are three reasons why that's the case.

Image source: Getty Images.

Continue reading

Source Fool.com